
Gilead Licensed Three T-Cell Engagers From Vir
Gilead Sciences secured rights to develop and commercialize three oncology programs from Vir Biotechnology.
Live Poll
Do you trust that multi-billion dollar pharmaceutical acquisitions will lead to better health outcomes for patients?





